GlassScriptPhysician profile
Ulka M Desai
NPI 1841481025
$5,769.77
in general payments reported to CMS, 2019-2025
28 companies · $2,088 in 2025
The $2,088 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $315 · 2021: $461 · 2022: $850 · 2023: $544 · 2024: $599 · 2025: $2,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,229.43 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $701.98 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $601.86 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $595.58 | 2019-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $572.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $559.38 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $404.71 | 2019-2024 | Auryxia |
| Novartis Pharmaceuticals Corporation | $304.54 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $253.16 | 2019-2025 | Rayaldee |
| Amgen INC. | $218.42 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Fresenius USA Marketing, INC. | $216.52 | 2019-2025 | Velphoro |
| Aurinia Pharma U.S., INC. | $211.97 | 2022-2025 | Lupkynis |
| Ardelyx, INC. | $166.30 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $129.30 | 2024-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $128.51 | 2019-2023 | |
| Glaxosmithkline, LLC. | $124.05 | 2021-2025 | Benlysta, Shingrix, Arexvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $98.62 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $93.00 | 2025 | Filspari |
| Apellis Pharmaceuticals, INC. | $67.66 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.19 | 2024-2025 | Jardiance |
| Amarin Pharma, INC. | $46.67 | 2019-2020 | |
| Genzyme Corporation | $44.77 | 2023 | |
| Scpharmaceuticals INC. | $37.32 | 2025 | |
| Mallinckrodt Enterprises LLC | $31.52 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.47 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.15 | 2025 | |
| Shire North American Group INC | $19.53 | 2019 | |
| Recor Medical INC | $19.30 | 2025 | Paradise Ultrasound Renal Denervation System |
| Lilly USA, LLC | $19.00 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulka Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.